Newborn screening for SCID and severe T lymphocytopenia in Europe.

IF 11.4 1区 医学 Q1 ALLERGY
Maartje Blom, Maarja Soomann, Pere Soler-Palacín, Anna Šedivá, Asbjørg Stray-Pedersen, Rolf Zetterström, Carsten Speckmann, Andrew R Gennery, Mirjam van der Burg
{"title":"Newborn screening for SCID and severe T lymphocytopenia in Europe.","authors":"Maartje Blom, Maarja Soomann, Pere Soler-Palacín, Anna Šedivá, Asbjørg Stray-Pedersen, Rolf Zetterström, Carsten Speckmann, Andrew R Gennery, Mirjam van der Burg","doi":"10.1016/j.jaci.2024.10.018","DOIUrl":null,"url":null,"abstract":"<p><p>Initiation of newborn screening (NBS) programs in Europe dates back to the 1960s. One of the most recent expansions of NBS programs was the addition of severe combined immunodeficiency (SCID) based on detection of T-cell receptor excision circles (TRECs). In this review, we present an overview of the current situation in Europe. To avoid a biased overview based on only published results, a 37-item survey on TREC-based NBS was sent to representatives of 46 European countries. With a response rate of 83%, we collected data of 38 countries. Seventeen of the 38 European countries that have completed the survey have nationally or regionally implemented TREC-based NBS. The survey results emphasize similarities and differences as well as common practices and challenges in TREC-based NBS. Because TRECs are a general surrogate marker for severe T lymphocytopenia, conditions other than SCID are also identified. Therefore, the initial definition of the target disease as \"SCID\" might need to be reconsidered and extended to \"SCID and severe T lymphocytopenia.\" Even though complete harmonization of TREC-based NBS programs across Europe will remain challenging, collaboration and close partnerships will help in the move toward universal TREC-based screening for all newborns, resulting in more infants with SCID and severe T lymphocytopenia being detected each year.</p>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaci.2024.10.018","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Initiation of newborn screening (NBS) programs in Europe dates back to the 1960s. One of the most recent expansions of NBS programs was the addition of severe combined immunodeficiency (SCID) based on detection of T-cell receptor excision circles (TRECs). In this review, we present an overview of the current situation in Europe. To avoid a biased overview based on only published results, a 37-item survey on TREC-based NBS was sent to representatives of 46 European countries. With a response rate of 83%, we collected data of 38 countries. Seventeen of the 38 European countries that have completed the survey have nationally or regionally implemented TREC-based NBS. The survey results emphasize similarities and differences as well as common practices and challenges in TREC-based NBS. Because TRECs are a general surrogate marker for severe T lymphocytopenia, conditions other than SCID are also identified. Therefore, the initial definition of the target disease as "SCID" might need to be reconsidered and extended to "SCID and severe T lymphocytopenia." Even though complete harmonization of TREC-based NBS programs across Europe will remain challenging, collaboration and close partnerships will help in the move toward universal TREC-based screening for all newborns, resulting in more infants with SCID and severe T lymphocytopenia being detected each year.

欧洲新生儿 SCID 和严重 T 淋巴细胞减少症筛查。
欧洲的新生儿筛查(NBS)项目可追溯到 20 世纪 60 年代。NBS 项目的最新扩展之一是在检测 T 细胞受体切割圈 (TREC) 的基础上增加了重症联合免疫缺陷 (SCID) 的筛查。在本综述中,我们概述了欧洲的现状。为避免仅根据已发表的结果进行有失偏颇的概述,我们向 46 个欧洲国家的代表发送了一份有关基于 TREC 的 NBS 的 37 个项目的调查问卷。我们收集了 38 个国家的数据,回复率为 83%。在完成调查的 38 个欧洲国家中,有 17 个国家或地区实施了基于 TREC 的 NBS。调查结果强调了基于 TREC 的 NBS 的异同、共同做法和挑战。由于 TRECs 是严重 T 淋巴细胞减少症的一般替代标志物,因此还可确定 SCID 以外的其他病症。因此,最初将目标疾病定义为 "SCID "可能需要重新考虑,并扩展为 "SCID 和严重 T 淋巴细胞减少症"。尽管在欧洲范围内完全统一基于 TREC 的新生儿疾病筛查项目仍具有挑战性,但合作和密切的伙伴关系将有助于实现对所有新生儿进行基于 TREC 的普遍筛查,从而每年发现更多患有 SCID 和严重 T 淋巴细胞减少症的婴儿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
25.90
自引率
7.70%
发文量
1302
审稿时长
38 days
期刊介绍: The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信